Lead Product(s): LXE408
Therapeutic Area: Infections and Infectious Diseases
Highest Development Status: Phase I Product Type: Undisclosed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement February 25, 2020
Within the scope of the agreement, Novartis is responsible for completing Phase I clinical trials and DNDi will lead Phase II and Phase III development in India.